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Abstract
Rearrangements of 3q26 have been described in 5% of de novo or therapy
related acute myeloid leukemia, myelodysplastic syndrome (MDS), and
blast phase of chronic myeloid leukemia. The most common
translocations involving 3q26 are t(3;12)(q26;p13), t(3;21)(q26;q22),
t(3;3)(q21;q26), t(2;3)(p15∼23;q26∼27) and rarely t(3;7)(q26;q21).
However, t(3;8)(q26;q24) with or without monosomy 7 is a rare
phenomenon and has been reported in only 10 patients so far. Hereby, we
describe a 58 year old patient who was diagnosed with refractory anemia
with multilineage dysplasia. Cytogenetic studies revealed monosomy 7. He
was then lost to follow-up. A year later he was found to have worsening
cytopenias and circulating blasts. He was started on azacytidine. A month
later, follow-up bone marrow biopsy showed progression to acute myeloid
leukemia (76% blasts). The blasts showed following immunophenotypic
profile: CD7+, CD10-, CD13+, CD14-, CD16-, CD33+, CD38+, CD56-,
CD64-, CD117-, HLA-DR+, MPO-, cCD3-, cCD22-, cCD79- and TdT-. His
karyotype showed evolution with additional finding of t(3;8) which
involved MYC gene at 8q24 which was confirmed with metaphase FISH.
The breakpoint on 3q26 is most likely the EVI1 fusing with MYC. Even
though monosomy 7 has been frequently described to be associated with
t(3;8), it is not described as a predecessor of t(3;8). Patient failed first
induction chemotherapy. He is currently finishing up his re-induction
chemotherapy. This case describes a case of AML arising from MDS with
monosomy 7 and involving MYC gene as a partner for 3q26 (EVI1).

Case
We describe a 58 year old patient who was diagnosed with refractory
anemia with multilineage dysplasia. Cytogenetic studies revealed
monosomy 7. He was then lost to follow-up. A year later he was found
to have worsening cytopenias and circulating blasts. He was started on
azacytidine. A month later, follow-up bone marrow biopsy showed
progression to acute myeloid leukemia (76% blasts) (Figure 1). The
blasts showed the following immunophenotypic profile: CD7+, CD10-,
CD13+, CD14-, CD16-, CD33+, CD38+, CD56-, CD64-, CD117-, HLADR+, MPO-, cCD3-, cCD22-, cCD79- and TdT-. His karyotype showed
evolution with additional finding of t(3;8) (Figure 2) which involved
MYC gene at 8q24 which was confirmed with metaphase fluorescence
in situ hybridization (FISH) (Figure 3). The breakpoint on 3q26 is most
likely the EVI1 fusing with MYC. Even though monosomy 7 has been
frequently described to be associated with t(3;8), it is not described as a
predecessor of t(3;8). The patient failed two rounds of induction
chemotherapy. This case describes a case of AML arising from MDS
with monosomy 7 and involving MYC gene as a partner for 3q26
(EVI1).

Figure 2: Karyotype shows all 20 GTW banded cells with monosomy 7. Four of
these cells also showed an additional material of unknown origin on the long
arm of chromosome 8.
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Introduction
Ecotropic viral integration site 1 (EVI1) gene was first identified in murine
myeloid leukemia.2 EVI1 was later recognized as a proto-oncogene located
on human chromosome 3q26 and associated with the pathogenesis of
human acute myeloid leukemia (AML) or myelodysplastic syndrome
carrying 3q26 rearrangement. EVI1 contains 16 exons spanning 64.2
kilobases.3 It encodes a protein belonging to a family of DNA-binding zinc
finger proteins.
Rearrangements of 3q26 have been described in 5% of de novo or therapy
related acute myeloid leukemia, myelodysplastic syndrome, and blast
phase of chronic myeloid leukemia.4 The most common translocations
involving 3q26 are t(3;12)(q26;p13), t(3;21)(q26;q22), t(3;3)(q21;q26),
t(2;3)(p15∼23;q26∼27) and rarely t(3;7)(q26;q21).2,3 However, t(3;8)
(q26;q24) with or without monosomy 7 is a rare phenomenon and has
been reported in only 10 patients so far.
Characteristic features of t(3;8)(q26;q24) are described in previous cases
and includes anemia, trilineage dysplasia, megakaryocytic hyperplasia,
thrombocytosis.2 These patients with this specific translocation have poor
prognosis.4,5 Patients with 3q26 rearrangement generally have poor
response to therapy.1
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Figure 3: FISH shows monosomy 7 and MYC gene rearrangement with 3q.
BCL6 gene rearrangement at 3q27 is negative (A); EGR1/D5S21, D5S23 for
-5/5q- is negative (B); D7S522/7 cen for -7/del(7q) is positive in 92.5% of nuclei
(C); CEP8 for aneusomy 8 is negative (D); MYC for rearrangement of 8q24 is
positive in 86.5% of nuclei (E); D20S108 deletion at 20q12 is negative (F).
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Figure 1: Peripheral blood smear showing circulating blasts (A), WrightGiemsa stain, 100x oil. Aspirate smear shows sheets of blasts (B), WrightGiemsa stain, 100x oil. Bone marrow core biopsy shows hypercellular
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Hematoxylin and eosin stain, 40x) and immunohistochemical stain for
CD34 (D) highlights the blasts, 40x.
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